Management of COPD according to guidelines. A national survey among Belgian physicians

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 59, Issue 1, 2003, Pages 62-80

  Decramer, Marc ^a   Bartsch, P ^b   Pauwels, R ^c   Yernault, J C ^d   Bruart, J ^e   Buffels, J ^e   Cnockaert, P ^e   Coolen, D ^e   De Backer, W ^e   Degives, R ^e   Degryse, J M ^e   Demedts, M ^e   Derom, E ^e   De Vuyst, P ^e   Dewaele, R ^e   Diels, R ^e   Dierckx, J P ^e   Garzaniti, N ^e   Gepts, L ^e   Gillard, C ^e   Haenebalcke, C ^e   Heyrman, J ^e   Hoengenaert, J P ^e   Louis, R ^e   Marchand, E ^e   Meysman, M ^e   Minguet, C ^e   Pestiaux, D ^e   Robience, Y ^e   Rodenstein, D ^e   Sergysels, R ^e   Van Bragt, J ^e   Vander Elst, B ^e   Vermeire, P ^e   Vincken, W ^e   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e NONE

Author keywords

COPD; Diagnosis; GOLD; Guidelines; Management

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MUCOLYTIC AGENT; NICOTINE DERIVATIVE; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; BELGIUM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; MALE; MEDICAL SPECIALIST; NICOTINE REPLACEMENT THERAPY; OXYGEN THERAPY; PHYSICIAN ATTITUDE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; REHABILITATION CENTER; SMOKING CESSATION; SPIROMETRY; SYSTEMIC THERAPY; TOBACCO DEPENDENCE;

EID: 0141483616     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. The GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 2001; 163: 1256-1276.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997; 349: 1436-1442.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997; 349: 1498-1504.
4. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey 1988-1994. Arch Intern Med 2000; 160: 1683-1689.
5. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: Subjects' perspective of confronting COPD international survey. Eur Respir J, 2002; 20: 799-805.
6. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J, 2000; 16: 802-807.
7. Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM, and the EFRAM investigators. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J, 2000; 16: 1037-1042.
8. ATS Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121.
9. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J, 1995; 8: 1398-1420.
10. BTS. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Guidelines for the management of chronic obstructive pulmonary disease. Thorax, 1997; 52: S1-S28.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Executive Report. National Institutes of Health. National Heart, Lung and Blood Institute. Publication Number 2701. April 2001.
12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Workshop Summary. National Institutes of Health. National Heart, Lung and Blood Institute. Publication Number 2701. April 2001.
13. Den Otter J, Van Dijk B, Van Schayck CP, Molema J, Van Weel C. How to avoid underdiagnosed asthma/chronic obstructive pulmonary disease? J Asthma, 1998; 35: 381-387.
14. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry improves early detection of COPD in general practice. Practice in Didasco study. Am J Respir Crit Care Med, 2002; 165: A 654.
15. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med, 1999; 340: 1948-1953.
16. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet, 1999; 353: 1819-1823.
17. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. Br Med J, 2000; 320: 1297-1303.
18. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Eng J Med, 2000; 343: 1902-1909.
19. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2001; 164: 580-584.
20. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, Joseph AM, Niewoehner DE. Withdrawal of chronic systemic corticosteroids in patients with COPD A randomized trial Am J Respir Crit Care Med, 2000; 162: 174-178.
21. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med, 1994; 150: 11-16.
22. Decramer M, Stas KJ. Corticosteroid-induced muopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med, 1992; 146: 800-802.
23. Troosters T, Rabinovich R, Gosselink R, Rodriguez-Roisin R, Decramer M, Roca J. COPD patients show regional differences in functional status within Europe. Am J Respir Crit Care Med, 2001; 163: A 648.
24. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. The department of veterans affairs cooperative study group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Eng J Med, 1999; 340: 1941-9147.
25. Davies L, Angus RM and Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet, 1999; 354: 456-460.
26. Anthonisen NR, Manfreda J, Waren CPW, Hersfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 1987; 106: 196-204.
27. International consensus conferences in intensive care medicine: Noninvasive positive pressure ventilation in acute respiratory failure organized jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Société de Réanimation de Langue Française, and approved by the ATS Board of Directors, December 2000. Am J Respir Crit Care Med, 2001; 163: 283-291.
28. Bott J, Carroll MP, Conway JH, Keilty SEJ, Ward EM, Brown AM, Paul EA, Elliott MW, Godfrey RC, Wedzicha JA, Moxham. Randomized controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet, 1993; 341: 1555-1557.
29. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F, Isabey D, Harf A. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Eng J Med, 1995; 333: 817-822.
30. Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med, 1995; 151: 1799-1806.
31. Plant PK, Owen JL and Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial. Lancet, 2000; 355: 1931-1935.
32. Goldstein RS, Gort EH, Stubbing D, et al. Randomized controlled trial of respiratory rehabilitation. Lancet, 1994; 344: 1394-1397.
33. Reis AL, Kaplan RM, Limberg TMK, et al. Effects of pulmonary rehabilitation on physiological and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med, 1995; 122: 823-832.
34. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet, 1996; 348: 1115-1119.
35. Wedzicha JA, Bestall JC, Garrod R, et al. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J, 1998; 12: 363-369.
36. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: A randomised controlled trial. Lancet, 2000; 355: 362-368.
37. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: A randomised trial. Am J Med, 2000; 109: 207-212. Lacasse, et al. Cochrane database Syst Rev CD003793.
38. Tønnesen P, Paoletti P, Gustavsson G, Russell MA, Sacacci R, Gulsvik A, Rijcken B, Sawe U, members of the Steering Committee of CEASE on behalf of the European Respiratory Society. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Eur Respir J, 1999; 13: 238-246.
39. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library. BMJ, 2000; 321: 355-358.
40. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA, 1994; 272: 1497-1505.